Cefadroxil
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Cefadroxil is a cephalosporin that is FDA approved for the treatment of urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species, skin and skin structure infections caused by staphylococci and/or 4streptococci, pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Urinary Tract Infections
- For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.).
- For all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.).
Skin and Skin Structure Infections
For skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.).
Pharyngitis and Tonsillitis
Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis-1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Cefadroxil in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Cefadroxil in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of Cefadroxil should be administered for at least 10 days.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Cefadroxil in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Cefadroxil in pediatric patients.
Contraindications
Cefadroxil monohydrate is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
Warnings
Before therapy with Cefadroxil monohydrate is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefadroxil, cephalosporins, penicillins, or other drugs. if this product is to be given to penicillin-sensitive patients, caution should be exercised because cross-sensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefadroxil monohydrate occurs, discontinue the drug. serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefadroxil, and may range from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicated that a toxin produced by Clostridium difficile is a primary cause of “antibiotic-associated colitis’’. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug effective against Clostridium difficile.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Cefadroxil Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Cefadroxil Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Cefadroxil Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Cefadroxil in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cefadroxil in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Cefadroxil during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Cefadroxil in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Cefadroxil in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Cefadroxil in geriatric settings.
Gender
There is no FDA guidance on the use of Cefadroxil with respect to specific gender populations.
Race
There is no FDA guidance on the use of Cefadroxil with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Cefadroxil in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Cefadroxil in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Cefadroxil in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Cefadroxil in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Cefadroxil Administration in the drug label.
Monitoring
There is limited information regarding Cefadroxil Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Cefadroxil and IV administrations.
Overdosage
There is limited information regarding Cefadroxil overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Cefadroxil Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Cefadroxil Mechanism of Action in the drug label.
Structure
There is limited information regarding Cefadroxil Structure in the drug label.
Pharmacodynamics
There is limited information regarding Cefadroxil Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Cefadroxil Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Cefadroxil Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Cefadroxil Clinical Studies in the drug label.
How Supplied
There is limited information regarding Cefadroxil How Supplied in the drug label.
Storage
There is limited information regarding Cefadroxil Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Cefadroxil |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Cefadroxil |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Cefadroxil Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Cefadroxil interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Cefadroxil Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Cefadroxil Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [4]
Overview
Cefadroxil (formerly trademarked as Duricef) is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections. It is a bactericidal antibiotic.
Category
Cephalosporin, First-Generation
US Brand Names
DURICEF®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied
Mechanism of Action
Cefadroxil belongs to the first-genaration Cephalosporins.Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin-binding proteins (PBPs).